Catalyst
Slingshot members are tracking this event:
Shire's (SHPG) Cinryze Approved for Expanded Indication in Europe to Prevent and Treat Hereditary Angioedema (HAE) Attacks in Pediatric Patients with HAE
- Source Link:
- https://www.shire.com/en/newsroom/2017/march/h74733
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SHPG |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 16, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cinryze, Expanded Indication, Prevention, Treatment, Hereditary Angioedema, Hae, Pediatric Patients
